Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

InflaRx Reports Topline Results From Multiple Ascending Dose Part Of Its Randomized, Double-blind, Placebo-controlled Phase I Trial For INF904; To Advance INF904 Into Phase II Clinical Development

Author: Benzinga Newsdesk | January 04, 2024 08:03am

INF904 was well tolerated and there were no adverse safety events of concern after repeated dosing in participants over the entire tested dose range.

Posted In: IFRX